Anti-CEACAM5/CEA/CD66e Antibody (Labetuzumab govitecan)
Catalog No.
F1557
Anti-CEACAM5/CEA/CD66e Antibody (Labetuzumab govitecan)
Featured Products
Labetuzumab govitecan (IMMU 130) is an anti-CEACAM5/SN-38 antibody-active molecule conjugate (ADC). Labetuzumab govitecan is composed of the antibody Labetuzumab, SN-38, and a pH-sensitive linker. Labetuzumab govitecan can be used in cancer research, such as colorectal cancer.
145.48 kDa
Dry ice
1469876-18-3
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
IMMU-130, hMN-14-SN38
100 mM Pro 20 mM Arg pH 5.0. No preservative!
P06731
Human
SN38
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
Human CEACAM5 / CEA / CD66e HEK293 Cell Line were stained Anti-CEACAM5/CEA/CD66e Antibody (Labetuzumab govitecan) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, The EC50 is 1.45 ug/mL.
CEACAM5 / CEA / CD66e
Please avoid freeze-thaw cycles.